Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

Volume: 116, Pages: 158 - 168
Published: Jul 1, 2019
Abstract
Background Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status in the context of cabazitaxel therapy is unknown. Patients and methods Between September 2011 and January 2018, pretherapy plasma samples...
Paper Details
Title
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
Published Date
Jul 1, 2019
Volume
116
Pages
158 - 168
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.